Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.

[2] Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.

[3] Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.

Rigosertib is a microtubule-destabilizing agent.

This antineoplastic or immunomodulatory drug article is a stub.